Levemir Shortage: What Providers and Prescribers Need to Know in 2026

Provider Briefing: Levemir Discontinuation and Shortage

Novo Nordisk's decision to discontinue Levemir (Insulin Detemir) has created a significant supply disruption that directly impacts patient care across endocrinology, internal medicine, family medicine, and pediatric practices. This article provides a comprehensive overview for prescribers navigating the transition in 2026.

If you're looking for actionable steps to help individual patients, see our companion guide: How to help your patients find Levemir in stock.

Timeline of the Levemir Discontinuation

Understanding the timeline helps contextualize the current supply situation:

• June 2005: Levemir (Insulin Detemir) receives FDA approval for use in type 1 and type 2 diabetes.
• 2023: Levemir ranks as the 153rd most commonly prescribed medication in the United States, with over 3 million prescriptions filled.
• Late 2024: Novo Nordisk announces plans to discontinue Levemir production, citing portfolio optimization and the availability of newer insulin products.
• 2025: Production winds down. Supply becomes increasingly spotty across U.S. pharmacies. ASHP Drug Shortage database lists Insulin Detemir.
• Early 2026: Supply continues to decline. Many chain pharmacies report zero stock. Independent pharmacies may retain limited inventory.
• December 2026 (projected): UK authorities estimate complete depletion of Levemir supplies. U.S. trajectory is similar.

Prescribing Implications

The discontinuation of Levemir raises several clinical considerations for prescribers:

No Biosimilar Available

Unlike Insulin Glargine, which has multiple biosimilar and interchangeable products (Basaglar, Semglee), there is no biosimilar for Insulin Detemir. This means there is no substitute product that can be dispensed at the pharmacy level without a new prescription. Every Levemir patient will eventually need a prescriber-initiated switch to an alternative basal insulin.

Dose Conversion Is Not 1:1

When transitioning patients from Levemir to alternative basal insulins, dose equivalency should not be assumed. General conversion guidance:

• Levemir → Insulin Glargine (Lantus/Basaglar/Semglee): Typically a unit-for-unit conversion is used as a starting point, but clinical judgment is needed. Patients on twice-daily Levemir may consolidate to once-daily Glargine.
• Levemir → Insulin Degludec (Tresiba): Start at approximately 80% of the total daily Levemir dose and titrate based on fasting glucose levels.
• Levemir → NPH Insulin: Consider splitting into two daily doses. The total daily dose of NPH is often similar, but the pharmacokinetic profile is significantly different, with a more pronounced peak at 4-12 hours.

Regardless of the conversion approach, increased glucose monitoring is recommended during the first 2-4 weeks of transition.

Impact on Pediatric Patients

Levemir is approved for children aged 2 and older with type 1 diabetes. Pediatric endocrinology practices may face particular challenges, as some children have been stabilized on Levemir for years. Insulin Glargine is the most evidence-supported alternative in pediatric populations.

Pregnancy Considerations

Levemir has been widely used in pregnancy (Category B; Category A in Australia) with a strong safety profile. For pregnant patients currently on Levemir, transitioning to Insulin Detemir alternatives should be done carefully. Insulin Glargine and NPH Insulin both have pregnancy data, though NPH has the longest track record.

Current Availability Picture

As of early 2026, Levemir availability varies significantly by geography and pharmacy type:

• Chain pharmacies (CVS, Walgreens, Rite Aid): Most report limited or zero stock of Levemir.
• Independent pharmacies: Some retain limited inventory through alternative wholesale channels.
• Specialty pharmacies: May have better access for patients with specific clinical needs.
• Mail-order pharmacies: Availability is inconsistent and declining.

Providers can use Medfinder for Providers to help patients identify pharmacies with current Levemir stock.

Cost and Access Considerations

The financial landscape for Levemir patients is evolving:

• Cash price: $350-$500 per box of 5 FlexTouch pens or per 10 mL vial.
• Insurance coverage: Many plans have removed Levemir from formularies or moved it to non-preferred tiers. Prior authorization requirements may have been added or coverage may be denied entirely.
• Manufacturer savings programs: Novo Nordisk's NovoCare savings card for Levemir may no longer be available as the product is discontinued.
• Patient assistance: The Novo Nordisk Patient Assistance Program (PAP) may still cover qualifying uninsured patients. Contact NovoCare at 1-866-310-7549.
• $35 insulin cap: The federal $35/month out-of-pocket cap applies to many insulin products under Medicare Part D and some commercial plans, but availability of Levemir itself is the primary barrier.

For a patient-facing resource on cost savings, see how to save money on Levemir.

Tools and Resources for Providers

Several resources can help you manage the transition for your patient panel:

• Medfinder for Providers: Real-time pharmacy stock lookup for Levemir and alternative insulins. Share with patients or use in clinical workflows.
• ASHP Drug Shortage Database: Monitor official shortage status and manufacturer updates.
• NovoCare (novocare.com): Novo Nordisk's patient support portal for assistance programs and transition resources.
• NeedyMeds (needymeds.org) and RxAssist (rxassist.org): Directories of patient assistance programs for insulin and other diabetes medications.

Looking Ahead

The Levemir discontinuation is a reminder of the fragility of single-source medication supply chains. As you transition patients to alternative basal insulins, consider the following long-term factors:

• Insulin Glargine biosimilars (Basaglar, Semglee) offer the most accessible and cost-effective transition path for the majority of patients.
• Insulin Degludec (Tresiba) is a strong option for patients who need dosing flexibility or who have experienced nocturnal hypoglycemia on other basal insulins.
• NPH Insulin remains a viable option for cost-sensitive patients, though it requires more intensive monitoring due to its pharmacokinetic profile.
• Proactively transitioning patients now, rather than waiting for complete supply exhaustion, reduces the risk of gaps in insulin therapy.

Final Thoughts

The discontinuation of Levemir affects a substantial patient population. Proactive, planned transitions to alternative basal insulins — combined with increased glucose monitoring and patient education — will minimize disruption to glycemic control.

Use Medfinder for Providers to help patients locate remaining Levemir stock and to identify availability of alternative insulins at local pharmacies. For patient-facing information you can share, see our articles on Levemir alternatives and the Levemir shortage update for patients.